Big pharma won’t stop raising prices in 2017 — it’ll just do it smarter

Big pharma won’t stop raising prices in 2017. But it will start doing it smarter.

Critics found it easy to vilify Mylan Inc. MYL, -0.53% as a heartless corporation making a lifesaving product — the EpiPen treatment for allergic reactions — economically out-of-reach for children. And the industry has learned its lessons from the fallout, experts say.

Pharmaceutical companies were once able to decry price hikers as a few “bad actors” that weren’t representative of their industry, but that was in 2015. Mylan was firmly one of their own, and plenty of others were making big price increases in 2016, Sanofi SNY, +0.31% AbbVie Inc.

>>> Original Source <<<